Talphera
NASDAQ: TLPHSan Mateo, US · Delaware corporation
Talphera is a pharmaceutical company developing and commercializing therapies for medically supervised settings, with a lead candidate, Niyad (nafamostat mesylate), a regional anticoagulant for the extracorporeal circuit during renal replacement therapy. Its pipeline also includes nafamostat-based products for inflammatory and antiviral indications and ready-to-use prefilled syringes of ephedrine and phenylephrine for perioperative and acute-care use.
Founders & leadership
PP
Pamela P. PalmerFounder
BP
Badri P DasuExecutive
SA
Shakil AslaminExecutive
VJ
Vincent J. AngottiExecutive
RA
Raffi AsadorianExecutive
Board
MW
Mark WanBoard director
AJ
Abhinav JainBoard director
MB
Marina BozilenkoBoard director
JB
Jill BroadfootBoard director
SJ
Stephen J. HoffmanBoard director
AA
Adrian AdamsBoard director
RA
Richard AfableBoard director
Reported raises · per SEC filings
Form D private placements$43.7M disclosed across 6 rounds · 2022–2025
▶$17MraisedSep 2025 · 13 investors · PharmaceuticalsRule 506(b)
▶$17MraisedSep 2025 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Adrian AdamsDirector
- Shakil AslamExecutive Officer
- Abhinav JainDirector
- Vincent J AngottiExecutive Officer, Director
- Marina BozilenkoDirector
- Raffi AsadorianExecutive Officer
- Mark WanDirector
- Jill BroadfootDirector
- Stephen J HoffmanDirector
- Badri P DasuExecutive Officer
- Offering amount
- $29M
- Amount sold
- $17M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.9MraisedApr 2025 · 11 investors · PharmaceuticalsRule 506(b)
▶$4.9MraisedApr 2025 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mark WanDirector
- Badri P DasuExecutive Officer
- Abhinav JainDirector
- Shakil AslamExecutive Officer
- Marina BozilenkoDirector
- Vincent J AngottiExecutive Officer, Director
- Jill BroadfootDirector
- Stephen J HoffmanDirector
- Adrian AdamsDirector
- Raffi AsadorianExecutive Officer
- Offering amount
- $15M
- Amount sold
- $4.9M
- Sales commissions
- $1.1M
- Placement agents
- A.G.P./Alliance Global Partners, BTIG, LLC
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedJan 2024 · 6 investors · PharmaceuticalsRule 506(b)
▶$6MraisedJan 2024 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Richard AfableDirector
- Adrian AdamsDirector
- Pamela P PalmerExecutive Officer, Director
- Marina BozilenkoDirector
- Howard B RosenDirector
- Stephen J HoffmanDirector
- Vincent J AngottiExecutive Officer, Director
- Raffi AsadorianExecutive Officer
- Badri DasuExecutive Officer
- Abhinav JainDirector
- Jill BroadfootDirector
- Mark WanDirector
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedJul 2023 · 10 investors · PharmaceuticalsRule 506(b)
▶$10MraisedJul 2023 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Adrian AdamsDirector
- Pamela P. PalmerDirector
- Jill BroadfootDirector
- Vincent J. AngottiExecutive Officer, Director
- Richard AfableDirector
- Marina BozilenkoDirector
- Mark WanDirector
- Raffi AsadorianExecutive Officer
- Howard B. RosenDirector
- Stephen J. HoffmanDirector
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $625K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$630KraisedAug 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$630KraisedAug 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stephen J. HoffmanDirector
- Jill BroadfootDirector
- Pamela P. PalmerExecutive Officer, Director
- Mark WanDirector
- Richard AfableDirector
- Vincent J. AngottiExecutive Officer, Director
- Raffi AsadorianExecutive Officer
- Marina BozilenkoDirector
- Howard B. RosenDirector
- Badri DasuExecutive Officer
- Adrian AdamsDirector
- Offering amount
- $630K
- Amount sold
- $630K
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedJan 2022 · 32 investors · PharmaceuticalsRule 506(b)
▶$5.2MraisedJan 2022 · 32 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mark WanDirector
- Badri DasuExecutive Officer
- Howard RosenDirector
- Vincent AngottiExecutive Officer, Director
- Stephen HoffmanDirector
- Mark EdwardsDirector
- Marina BozilenkoDirector
- Jill BroadfootDirector
- Adrian AdamsDirector
- Raffi AsadorianExecutive Officer
- Pamela PalmerExecutive Officer, Director
- Richard AfableDirector
- Offering amount
- $6M
- Amount sold
- $5.2M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Talphera do?
- Talphera is a pharmaceutical company developing and commercializing therapies for medically supervised settings, with a lead candidate, Niyad (nafamostat mesylate), a regional anticoagulant for the extracorporeal circuit during renal replacement therapy. Its pipeline also includes nafamostat-based products for inflammatory and antiviral indications and ready-to-use prefilled syringes of ephedrine and phenylephrine for perioperative and acute-care use.
- Who founded Talphera?
- Talphera was founded by Pamela P. Palmer.
- How much funding has Talphera raised?
- Talphera has disclosed $43.7M raised across 6 rounds.
- Where is Talphera headquartered?
- Talphera is headquartered in San Mateo, US.